Nga ra mắt thuốc điều trị COVID-19 đầu tiên được cấp phép

Ngày 11/6, Nga đã cho ra mắt loại thuốc điều trị bệnh viêm đường hô hấp cấp COVID-19 đầu tiên được cấp phép với tên gọi Avifavir, trong bối cảnh số ca mắc bệnh ở nước này đã vượt quá mốc 500.000 người.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Chứng nhận tín nhiệm mạng
POWERED BY Việt Long